Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present
data from 19 clinical studies at the 2015 American Society of
Clinical Oncology annual meeting to be held May 29 to June 2, 2015
in Chicago, Ill. Key podium presentations will highlight new
prospective research programs with advanced companion diagnostic
and molecular diagnostic tests aimed at revolutionizing how we
treat and prevent cancers. Abstracts of the Company's presentations
are available at: abstracts.asco.org.
"Advances in personalized medicine will include selecting
effective pharmaceuticals (companion diagnostics), preventing
disease (hereditary caner tests) and in optimizing treatment
decisions (prognostic tests). This meeting showcases our pioneering
research in these three areas of personalized medicine. In
companion diagnostics, the myChoice™ HRD test can transform the way
we personalize treatment plans for ovarian and breast cancers today
and many other cancers in the future," said Mark Capone, president
Myriad Genetic Laboratories. "Another critical goal for
personalized medicine is to prevent cancer. Our myRisk™
hereditary cancer panel test does just that by analyzing 25 genes
associated with eight common hereditary cancers. Lastly, our
prognostic tests demonstrate advances in optimizing treatments
decisions in prostate cancer and lung cancer. As a pioneer in
the field of personalized medicine, we remain firmly committed to
scientific progress through outstanding research that can
ultimately benefit patients."
The list of key Myriad presentations follows.
1. COMPANION
DIAGNOSTIC PRESENTATIONS |
myChoice HRD™: Podium
Presentation |
Title: |
Prediction of pathological complete response
(pCR) by homologous recombination deficiency (HRD) after
carboplatin-containing neoadjuvant chemotherapy in patients with
TNBC: results from GeparSixto. |
Presenter: |
Gunter Von Minckwitz |
Date: |
Monday, June 1, 4:12 – 4:24 p.m. |
Location |
N Hall B1; Abstract: 1004 |
|
|
myChoice HRD: Poster
Discussion Sessions |
Title: |
Phase II neoadjuvant clinical trial of
carboplatin and eribulin in women with triple negative early stage
breast cancer (NCT01372579). |
Presenter: |
Virginia Kaklamani |
Date: |
Saturday, May 30, 8:00 to 11:30 a.m. |
Location: |
N Hall B1; Abstract: 1017, Poster: 131 |
|
|
Title: |
Combined homologous recombination deficiency
(HRD) scores and response to neoadjuvant platinum-based
chemotherapy in triple negative and/or BRCA1/2 mutation associated
breast cancer. |
Presenter: |
Melinda Telli |
Date: |
Saturday, May 30, 8:00 to 11:30 a.m. |
Location: |
N Hall B1; Abstract: 1018, Poster: 132 |
|
|
myChoice HRD: Poster
Sessions |
Title: |
Reproducibility of homologous recombination
deficiency (HRD) scores in biopsies of triple negative breast
cancer (TNBC) tumors. |
Presenter: |
Kirsten Timms |
Date: |
Saturday, May 30, 8:00 to 11:30 a.m. |
Location: |
Abstract: 1091, Poster: 205 |
|
|
Title: |
Association of tumor BRCA1 reversion mutation
arising during neoadjuvant platinum-based therapy in breast cancer
(BC) with therapy resistance. |
Presenter: |
Anosheh Afghahi |
Date: |
Saturday, May 30, 8:00 to 11:30 a.m. |
Location: |
Abstract: 1094, Poster: 208 |
|
|
Title: |
Characteristics of homologous recombination
deficiency (HRD) in paired primary and recurrent high-grade serous
ovarian cancer (HGSOC). |
Presenter: |
Jai Patel |
Date: |
Saturday, May 30, 1:15 to 4:45 p.m. |
Location: |
Abstract: 5534, Poster: 92 |
|
|
Title: |
Use of homologous recombination deficiency
(HRD) score to enriche for niraparib sensitive high grade ovarian
tumors. |
Presenter: |
Keith Wilcoxen |
Date: |
Saturday, May 30, 1:15 to 4:45 p.m. |
Location: |
Abstract: 5532, Poster: 90 |
|
|
Title: |
Homologous recombination (HR) deficiency,
tumor BRCA1/2 mutations (tmBRCA) and association with response and
outcome following platinum monotherapy in high grade serous ovarian
cancer (HGSOC). |
Presenter: |
Robert Brown |
Date: |
Saturday, May 30, 1:15 to 4:45 p.m. |
Location: |
Abstract: 5576, Poster: 134 |
|
|
BRACAnalysis CDx™: Poster
Session |
|
|
Title: |
A randomized, placebo-controlled phase II
trial comparing gemcitabine monotherapy to gemcitabine in
combination with AZD 1775 (MK 1775) in women with recurrent,
platinum-resistant epithelial ovarian, primary peritoneal or
Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago,
and California consortia. |
Presenter: |
Stephanie Lheureux |
Date: |
Saturday, May 30, 1:15 to 4:45 p.m. |
Location: |
Abstract: TPS5613, Poster: 167a |
|
|
2. HEREDITARY
CANCER PRESENTATIONS |
myRisk™ Hereditary
Cancer: Podium Presentation |
Title: |
Predisposing germline mutations in high grade
ER+HER2- breast cancer (BC) patients diagnosed <age 50. |
Presenter: |
Judy Garber |
Date: |
Saturday, May 30, 2:15 to 2:27 p.m. |
Location: |
S 100BC; Abstract: 1503 |
|
|
myRisk Hereditary Cancer:
Poster Discussion Sessions |
Title: |
Outcomes of clinical testing for 50,000
patients utilizing a panel of 25 genes associated with increased
risk for breast, ovarian, colorectal, endometrial, gastric,
pancreatic, melanoma and prostate cancers. |
Presenter: |
Eric Rosenthal |
Date: |
Monday, June 1, 1:15 to 4:45 p.m. |
Location: |
S102, Abstract: 1515, Poster: 338 |
|
|
Title: |
Assessment of the clinical presentation for
patients discovered to have at least two deleterious mutations on
multigene panel testing. |
Presenter: |
Jeff Weitzel |
Date: |
Monday, June 1, 1:15 to 4:45 p.m. |
Location: |
S102, Abstract: 1514, Poster: 337 |
|
|
myRisk Hereditary Cancer:
Poster Session |
|
|
Title: |
A study of triple-negative breast cancer
patients tested with a 25-gene panel of hereditary cancer
genes. |
Presenter: |
John Sandbach |
Date: |
Saturday, May 30, 8:00 to 11:30 a.m. |
Location: |
Abstract: 1067, Poster: 181 |
|
|
Title: |
Multi-gene panel testing in an unselected
endometrial cancer cohort. |
Presenter: |
Kari Ring |
Date: |
Monday, June 1, 1:15 to 4:45 p.m. |
Location: |
Abstract: 1533, Poster: 357 |
|
|
3. PROGNOSTIC TEST
PRESENTATIONS |
|
|
myPlan® Lung Cancer:
Poster Session |
|
|
Title: |
Validation of a cell cycle progression score
for 5-year mortality risk in patients with stage I non-small cell
lung cancer. |
Presenter: |
Takashi Eguchi |
Date: |
Monday, June 1, 8:00 to 11:30 a.m. |
Location: |
Abstract: 7522, Poster: 269 |
|
|
Prolaris®: Poster
Session |
|
|
Title: |
Performance of CCP assay in an updated series
of biopsy samples obtained from commercial testing. |
Presenter: |
John Davis |
Date: |
Saturday, May 30, 1:15 to 4:45 p.m. |
Location: |
Abstract: 5033, Poster: 25 |
|
|
Prolaris: Abstract
Publications |
|
|
Title: |
Validation of an active surveillance
threshold for the CCP score in conservatively managed men with
localized prostate cancer. |
Author: |
Jack Cuzick. Abstract: e16040 |
|
|
Title: |
Impact of CCP test on personalizing treatment
decisions: results from a prospective registry of newly diagnosed
prostate cancer patients. |
Author: |
Neal Shore. Abstract: e16042 |
|
|
Title: |
Evaluation of the economic impact of the CCP
assay in localized prostate cancer. |
Author: |
David Crawford. Abstract: e16037 |
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions, and
assess risk of disease progression and recurrence. Myriad is
focused on strategic initiatives to grow existing markets,
diversify through the introduction of new products, including
companion diagnostics, and expand internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung
Cancer, BRACAnalysis CDx, MyChoice HRD, Vectra and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. in the
United States and foreign countries. MYGN-F, MYGN-G
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the
presentation of new clinical data on myChoice HRD, myRisk Herditary
Cancer, BRACAnalysis CDx, Prolaris and myPlan Lung Cancer at the
ASCO 2015 meeting; the ability of our new companion diagnostic
tests, such as myChoice™ HRD, to transform the way we personalize
treatment plans for ovarian and breast cancers today and many other
cancers in the future; the ability of our myRisk™ hereditary cancer
panel test to help prevent cancer; and the
Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to our
ability to transition from our existing to new testing services,
including unexpected costs and delays; risks related to decisions
or changes in the governmental or private insurers' reimbursement
levels for our tests or our ability to obtain reimbursement for our
new tests at comparable levels to our existing tests; risks related
to increased competition and the development of new competing tests
and services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities; risks related to public concern over our genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of in our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2014, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.